Industry News
Biotechnology Industry News
Aicuris has reported the success…
Aicuris has reported the success of a phase 3 trial, which has demonstrated the superiority of oral antiviral pritelivir compared to standard-of-care treatments in healing lesions of immunocompromised patients with refractory HSV infections. The study
The latest strand in Pelage…
The latest strand in Pelage Pharmaceuticals' growing funds comes from a $120 million series B fundraising round the biotech plans to apply to its regenerative hair loss treatment.
Company leaders at Bayer discuss…
Company leaders at Bayer discuss how integrating R&D and commercialization is transforming drug development for greater impact
BioCryst Pharmaceuticals has…
BioCryst Pharmaceuticals has struck a $700 million deal to buy Astria Therapeutics. The deal will give the rare disease specialist control of a phase 3 challenger to Takeda’s hereditary angioedema therapy Takhzyro.
Kailera Therapeutics has raised…
Kailera Therapeutics has raised $600 million to take its lead obesity program into phase 3. The series B round continues the meteoric rise of Kailera, which exited stealth with $400 million and ex-China rights to
Denali Therapeutics has become the…
Denali Therapeutics has become the latest on a growing list of biotechs to experience an FDA review delay in recent months.
Nascent cardiovascular biotech…
Nascent cardiovascular biotech Kardigan is continuing its bumper year with a pulse-quickening $254 million series B fundraising round, bringing the company’s total financing to more than half a billion dollars to support a tapestry of
Germany’s Tubulis has closed a…
Germany's Tubulis has closed a $361 million series C financing round with help from new investors Venrock Healthcare Capital Partners, Wellington Management and Ascenta Capital. The cash will help expand clinical development of Tubulis’ lead
The California biotech is…
The California biotech is developing a new drug class in hopes of redefining the standard of care for several allergic diseases.
Tvardi Therapeutics has failed its…
Tvardi Therapeutics has failed its first big test as a public company. Months after joining Nasdaq, the biotech has reported the unappetizing mix of high dropout rates and placebolike efficacy in a phase 2 trial
Gilead and Arcus’ anti-TIGIT…
Gilead and Arcus’ anti-TIGIT antibody domvanalimab has been tied to median overall survival of almost 27 months, keeping alive one of the last remaining hopes for this once-hyped modality.
Moderna has shared some of the…
Moderna has shared some of the phase 1/2 data that persuaded it to expand and prioritize development of a cancer candidate, reporting responses in melanoma patients failed by checkpoint inhibitors.
Novo Nordisk is ending all work in…
Novo Nordisk is ending all work in cell therapy, including a Type 1 diabetes program, amid CEO Maziar Mike Doustdar's reorganization. As part of the move, the company is laying off nearly all of the
Johnson & Johnson may be…
Johnson & Johnson may be looking to deepen its relationship with immunology partner Protagonist Therapeutics with a takeover deal, The Wall Street Journal reports.
After walking away from cell…
After walking away from cell therapy and narrowing its focus to just three modalities, Takeda is doubling down on its remaining strategic commitment by reupping a pact with AI drug designer Nabla Bio.
Cabaletta Bio’s CAR-T cell…
Cabaletta Bio’s CAR-T cell therapy successfully eliminated the overreactive B cells of two patients with an autoimmune disease, even without any preconditioning chemotherapy, pleasing investors and analysts alike and providing hope of less toxic autoimmune
In an Oct. 9 discussion about…
In an Oct. 9 discussion about innovation, resilience and the road ahead, panelists explored how federal uncertainty has affected the biotech sector, while also highlighting potential silver linings in the current environment.
The stars have aligned for Bristol…
The stars have aligned for Bristol Myers Squibb and Orbital Therapeutics. Pushing deeper into in vivo cell therapies, BMS has agreed to pay $1.5 billion to buy the biotech for a pipeline led by a
Shuttle Pharmaceuticals has…
Shuttle Pharmaceuticals has rocketed into the AI-driven drug discovery space via the planned $10 million acquisition of Molecule.ai.
It’s still early in the season,…
It’s still early in the season, but Evommune has become the latest indicator that drug developers are once again tempted by the public markets.